Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients

医学 不利影响 甲状腺髓样癌 内科学 队列 肿瘤科 甲状腺癌 癌症 胃肠病学
作者
Xiangqian Zheng,Meiyu Fang,Yun Fan,Yuping Sun,Meili Sun,Ankui Yang,Bin Zhang,Qinjiang Liu,Hui Liu,Xiaohong Zhou,Tao Huang,Jianwu Qin,Zhaohui Wang,Mengmeng Qin,Zhenwei Shen,Sheng Yao,Jason Yang,Yu Wang,Ming Gao
出处
期刊:Endocrine-related Cancer [Bioscientifica]
卷期号:31 (4) 被引量:4
标识
DOI:10.1530/erc-23-0134
摘要

Pralsetinib has demonstrated efficacious activity in various solid tumors, including medullary thyroid cancer (MTC), as observed in the phase 1/2 global ARROW study (BLU-667-1101; NCT03037385). We evaluated the safety and efficacy of pralsetinib in Chinese patients with advanced RET -mutant MTC. In the extension cohort of ARROW, adult patients with advanced MTC, who had not received systemic therapy (except for cytotoxic chemotherapy), were treated with pralsetinib (400 mg once daily, orally). The primary endpoints were blinded independent central-reviewed (BICR) objective response rate (ORR) and safety. Between October 9, 2019, and April 29, 2020, 34 patients were enrolled at 12 centers across China. Among them, 28 patients tested positive for RET mutations in the central laboratory, and 26 of these, with measurable disease at baseline per BICR, were included in the analysis set for tumor response. As of April 12, 2021 (data cutoff), the ORR was 73.1% (95% CI: 52.2–88.4), and the median duration of response was not reached. The most common (≥15%) grade ≥3 treatment-related adverse events (TRAEs) in the 28 patients with RET -mutant MTC were neutrophil count decreased (8/28, 28.6%), blood creatine phosphokinase increased (6/28, 21.4%), and lymphocyte count decreased (5/28, 17.9%). Serious TRAEs were reported by six patients (21.4%), with the most common event being pneumonia (3/28, 10.7%). No patient discontinued treatment or died from pralsetinib-related adverse events. Pralsetinib demonstrated broad, deep, and durable efficacy, as well as a manageable and acceptable safety profile in Chinese patients with advanced RET -mutant MTC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
徐哈哈发布了新的文献求助10
3秒前
5秒前
6秒前
7秒前
研友_VZG7GZ应助欣喜沛芹采纳,获得10
8秒前
感动黄豆完成签到,获得积分20
9秒前
10秒前
10秒前
12秒前
14秒前
Owen应助Kikua采纳,获得10
14秒前
juliar完成签到 ,获得积分10
14秒前
15秒前
Bressanone发布了新的文献求助10
15秒前
16秒前
彭于晏应助忐忑的阑香采纳,获得10
16秒前
赘婿应助xiaojian_291采纳,获得10
16秒前
17秒前
郭小宝发布了新的文献求助20
17秒前
糊涂的语兰完成签到,获得积分10
18秒前
浮生若梦完成签到 ,获得积分10
19秒前
CA发布了新的文献求助10
19秒前
忘记时间发布了新的文献求助30
19秒前
王羊补牢完成签到,获得积分10
21秒前
22秒前
潇湘雪月发布了新的文献求助10
27秒前
栗园应助仙都丽娜采纳,获得10
28秒前
严珍珍完成签到 ,获得积分10
28秒前
思源应助郭小宝采纳,获得10
28秒前
无理完成签到 ,获得积分10
29秒前
31秒前
31秒前
无端完成签到 ,获得积分20
31秒前
感动黄豆发布了新的文献求助10
32秒前
量子星尘发布了新的文献求助10
32秒前
33秒前
zwy109发布了新的文献求助10
34秒前
36秒前
立夏完成签到,获得积分10
37秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989242
求助须知:如何正确求助?哪些是违规求助? 3531393
关于积分的说明 11253753
捐赠科研通 3270010
什么是DOI,文献DOI怎么找? 1804868
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136